Organovo announced that they are joining together with two institutes from the National Institutes of Health (NIH) to help scientists develop more reliable tools for bringing safer, more effective treatments to patients on a faster timeline. Organovo is collaborating with the National Center for Advancing Translational Sciences (NCATS) and the National Eye Institute (NEI) to develop better and more clinically predictive tissue models using Organovo's NovoGen MMX Bioprinter(R). Organovo will collaborate with NCATS and NEI in using the NovoGen Bioprinting platform to create three-dimensional, architecturally correct, functional living tissues.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.5875 USD | -5.24% |
|
-17.83% | -47.07% |
05-31 | Organovo Holdings, Inc. Reports Earnings Results for the Full Year Ended March 31, 2024 | CI |
04-15 | Organovo's fatty liver disease drug meets main goal in mid-stage study | RE |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-47.07% | 8.91M | |
+24.74% | 47.96B | |
-0.47% | 42.45B | |
+43.96% | 41.47B | |
+25.40% | 31.6B | |
+17.96% | 28.63B | |
-4.47% | 28.03B | |
+50.73% | 14.56B | |
+42.56% | 14.14B | |
+1.46% | 12.58B |
- Stock Market
- Equities
- ONVO Stock
- News Organovo Holdings, Inc.
- Organovo Announces Collaboration with National Center for Advancing Translational Sciences and National Eye Institute to Develop Better and More Clinically Predictive Tissue Models Using Organovo's NovoGen MMX Bioprinter